Hypomania associated with mirtazapine augmentation of sertraline.
C A
CA
Soutullo
S L
SL
McElroy
P E
PE
Keck
D015057:1-Naphthylamine / Q000009:adverse effects / Q000031:analogs & derivatives*; D000553:Ambulatory Care; D014150:Antipsychotic Agents / Q000009:adverse effects*; D001714:Bipolar Disorder / Q000139:chemically induced*; D003866:Depressive Disorder / Q000188:drug therapy*; D004347:Drug Interactions; D004359:Drug Therapy, Combination; D019263:Dysthymic Disorder / Q000188:drug therapy; D005260:Female; D006801:Humans; D008803:Mianserin / Q000009:adverse effects / Q000031:analogs & derivatives*; D008875:Middle Aged; D000078785:Mirtazapine; D017367:Selective Serotonin Reuptake Inhibitors / Q000009:adverse effects*; D020280:Sertraline
D015057:1-Naphthylamine; D014150:Antipsychotic Agents; D008803:Mianserin; D000078785:Mirtazapine; D017367:Selective Serotonin Reuptake Inhibitors; D020280:Sertraline